Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Simeprevir,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hepatitis C Drugs Combined with Remdesivir Show Strong Effectiveness Against Covid-19, Study Finds
Details : Four HCV drugs, simeprevir, vaniprevir, paritaprevir, and grazoprevir-- in combination with remdesivir boosted the efficacy of remdesivir by 10-folds, the paper published in a reputed journal "Cell" reported.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2021
Lead Product(s) : Simeprevir,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Using MOGON II supercomputer, JGU reseachers found that compounds from the four hepatitis C drugs simeprevir, paritaprevir, grazoprevir, and velpatasvir have a high affinity to bind SARS-CoV-2.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2017
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2017
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Johnson & Johnson Innovative Medicine | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2015
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson Innovative Medicine | Yale University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2015
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 20, 2015
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2015
Lead Product(s) : Simeprevir
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2015
Lead Product(s) : Simeprevir
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2014
Lead Product(s) : Simeprevir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable